TARDBP and Alzheimer disease: In particular AD with comorbid TDP-43 pathology (Latimer and Liachko, 2021), because of their ability to reduce both tau and TDP-43 phosphorylation in cellulo and in vivo models (Sundaram et al., 2019; Martinez-Gonzalez et al., 2020; Halkina et al., 2021; Nozal et al., 2022).